Patents by Inventor David Shealy

David Shealy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11078267
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: August 3, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20200062841
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Application
    Filed: November 7, 2019
    Publication date: February 27, 2020
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 10519231
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: December 31, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20190248884
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Application
    Filed: February 25, 2019
    Publication date: August 15, 2019
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 10259867
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: April 16, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20190085069
    Abstract: An anti-IL-12 antibody or fragment thereof that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody or fragment thereof, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: December 4, 2018
    Publication date: March 21, 2019
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20180334500
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Application
    Filed: May 1, 2017
    Publication date: November 22, 2018
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20180079809
    Abstract: An anti-IL-12 antibody or fragment thereof that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody or fragment thereof, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: December 4, 2017
    Publication date: March 22, 2018
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 9862766
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: January 9, 2018
    Assignee: Janssen Biotech, inc.
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 9828424
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: November 28, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Patent number: 9676848
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 13, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20170157247
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: February 14, 2017
    Publication date: June 8, 2017
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 9605067
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: March 28, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20170029496
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Application
    Filed: June 30, 2016
    Publication date: February 2, 2017
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20160319014
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: July 22, 2016
    Publication date: November 3, 2016
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20160264659
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and thera
    Type: Application
    Filed: March 21, 2016
    Publication date: September 15, 2016
    Applicant: Janssen Biotech, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Patent number: 9428579
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: August 30, 2016
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 9409984
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: August 9, 2016
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 9321836
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: April 26, 2016
    Assignee: Janssen Biotech, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Publication number: 20150030608
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: October 13, 2014
    Publication date: January 29, 2015
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy